MX2022009025A - Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina. - Google Patents
Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina.Info
- Publication number
- MX2022009025A MX2022009025A MX2022009025A MX2022009025A MX2022009025A MX 2022009025 A MX2022009025 A MX 2022009025A MX 2022009025 A MX2022009025 A MX 2022009025A MX 2022009025 A MX2022009025 A MX 2022009025A MX 2022009025 A MX2022009025 A MX 2022009025A
- Authority
- MX
- Mexico
- Prior art keywords
- transthyretin
- compounds
- methods
- inhibiting
- compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 108010071690 Prealbumin Proteins 0.000 title 2
- 102000009190 Transthyretin Human genes 0.000 title 2
- 239000000203 mixture Substances 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000003941 amyloidogenesis Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 abstract 1
- 210000005003 heart tissue Anatomy 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000000578 peripheral nerve Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
- C07F9/65324—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan en la presente compuestos que tienen actividad contra enfermedades relacionadas con la TTR, y sales y solvatos farmacéuticamente aceptables de estos. También se proporcionan métodos para usar los compuestos para inhibir y prevenir la acumulación de TTR y/o formación de amiloide en los nervios periféricos, el riñón, el tejido cardíaco, los ojos y el SNC, y para tratar a un sujeto con amiloidosis de TTR periférica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966978P | 2020-01-28 | 2020-01-28 | |
| US202063009241P | 2020-04-13 | 2020-04-13 | |
| PCT/US2021/015271 WO2021154842A1 (en) | 2020-01-28 | 2021-01-27 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009025A true MX2022009025A (es) | 2022-10-07 |
Family
ID=74701564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009025A MX2022009025A (es) | 2020-01-28 | 2021-01-27 | Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230287021A1 (es) |
| EP (1) | EP4097092A1 (es) |
| JP (1) | JP2023512116A (es) |
| CN (1) | CN115298168A (es) |
| AU (1) | AU2021214076A1 (es) |
| BR (1) | BR112022014635A2 (es) |
| CA (1) | CA3166429A1 (es) |
| MX (1) | MX2022009025A (es) |
| WO (1) | WO2021154842A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023009585A2 (en) * | 2021-07-28 | 2023-02-02 | Protego Biopharma, Inc. | Transthyretin stabilizing compounds |
| CN114369071A (zh) * | 2021-12-10 | 2022-04-19 | 湖南第一师范学院 | 一种tafamidis中间体的合成方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1229037A1 (en) | 1996-06-28 | 2002-08-07 | Dow AgroSciences LLC | Heterocyclic N-acetonylbenzamides and their use as fungicides |
| ES2524803T3 (es) | 2002-12-19 | 2014-12-12 | The Scripps Research Institute | Composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento anómalo de la transtiretina |
| AU2005245470A1 (en) | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| TW200813035A (en) * | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
| PE20080888A1 (es) * | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
| US20100016387A1 (en) * | 2006-12-11 | 2010-01-21 | Avirup Bose | Method of treatment |
| WO2011116123A1 (en) * | 2010-03-19 | 2011-09-22 | Irm Llc | Tafamidis for the treatment of ophthalmic diseases |
| SG10201609188WA (en) | 2012-02-10 | 2016-12-29 | Ptc Therapeutics Inc | Compounds for treating spinal muscular atrophy |
| WO2013168014A1 (en) * | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| CN112608300B (zh) * | 2015-03-11 | 2024-04-26 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| US11414380B2 (en) | 2015-09-17 | 2022-08-16 | Eastman Chemical Company | Amphoteric compounds |
| WO2017148964A1 (en) | 2016-03-04 | 2017-09-08 | F. Hoffmann-La Roche Ag | New trifluoromethylpropanamide derivatives as htra1 inhibitors |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| EP3976017A4 (en) * | 2019-05-31 | 2023-06-14 | Plex Pharmaceuticals, Inc. | PHARMACOLOGICAL SUBSTANCES FOR THE TREATMENT OF PROTEIN AGGREGATION DISEASES OF THE EYE |
-
2021
- 2021-01-27 WO PCT/US2021/015271 patent/WO2021154842A1/en unknown
- 2021-01-27 MX MX2022009025A patent/MX2022009025A/es unknown
- 2021-01-27 CA CA3166429A patent/CA3166429A1/en active Pending
- 2021-01-27 BR BR112022014635A patent/BR112022014635A2/pt not_active Application Discontinuation
- 2021-01-27 US US17/759,265 patent/US20230287021A1/en active Pending
- 2021-01-27 EP EP21707835.1A patent/EP4097092A1/en active Pending
- 2021-01-27 AU AU2021214076A patent/AU2021214076A1/en active Pending
- 2021-01-27 JP JP2022572260A patent/JP2023512116A/ja active Pending
- 2021-01-27 CN CN202180021061.4A patent/CN115298168A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4097092A1 (en) | 2022-12-07 |
| BR112022014635A2 (pt) | 2022-10-11 |
| WO2021154842A1 (en) | 2021-08-05 |
| AU2021214076A1 (en) | 2022-08-04 |
| CA3166429A1 (en) | 2021-08-05 |
| US20230287021A1 (en) | 2023-09-14 |
| CN115298168A (zh) | 2022-11-04 |
| JP2023512116A (ja) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009025A (es) | Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina. | |
| JOP20220142A1 (ar) | مثبطات kras g12c | |
| PH12021550882A1 (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| EA201590345A1 (ru) | Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| MA54227B1 (fr) | Méthodes de traitement de la fibrose kystique | |
| PH12020550452A1 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) | |
| JO3789B1 (ar) | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
| NZ750817A (en) | Treatment and prevention of sleep disorders | |
| MX2021011488A (es) | Compuestos y usos de estos. | |
| MX2020012979A (es) | Métodos para aumentar la exposición al plasma de sepiapterina. | |
| BR112021022843A2 (pt) | Composto para tratamento de gota ou hiperuricemia | |
| MX2023001071A (es) | Tratamiento de la migraña. | |
| SA520420768B1 (ar) | مركبات بنزين سلفوناميد واستخدامها كعوامل علاجية | |
| GEP20237459B (en) | Thiadiazine derivatives | |
| MX2021005944A (es) | Inhibidores de rip1. | |
| WO2020128816A3 (en) | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent | |
| MX2021008903A (es) | Compuestos y usos de los mismos. | |
| PH12018502696A1 (en) | Heterocyclic prolinamide derivatives | |
| ATE386029T1 (de) | Urokinase-inhibitoren | |
| EA202190359A1 (ru) | Способы лечения нейродегенеративных расстройств | |
| MX2018016102A (es) | Derivados alifaticos de prolinamida. | |
| MX2019004200A (es) | Terapia de combinacion. | |
| MX2021015390A (es) | Tratamiento para sinucleinopatias. |